

Elena M Massarotti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6434519/publications.pdf>

Version: 2024-02-01

29
papers

3,848
citations

516215

16
h-index

525886

27
g-index

30
all docs

30
docs citations

30
times ranked

5266
citing authors

#	ARTICLE	IF	CITATIONS
1	2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2019, 71, 1400-1412.	2.9	1,098
2	Pathologically expanded peripheral T helper cell subset drives B cells in rheumatoid arthritis. <i>Nature</i> , 2017, 542, 110-114.	13.7	767
3	2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1151-1159.	0.5	759
4	The immune cell landscape in kidneys of patients with lupus nephritis. <i>Nature Immunology</i> , 2019, 20, 902-914.	7.0	501
5	Marked hyperferritinemia does not predict for HLH in the adult population. <i>Blood</i> , 2015, 125, 1548-1552.	0.6	170
6	Mixed-effects association of single cells identifies an expanded effector CD4 ⁺ T cell subset in rheumatoid arthritis. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	119
7	Cell-bound complement activation products in systemic lupus erythematosus: comparison with anti-double-stranded DNA and standard complement measurements. <i>Lupus Science and Medicine</i> , 2014, 1, e000056.	1.1	65
8	Use of Consensus Methodology to Determine Candidate Items for Systemic Lupus Erythematosus Classification Criteria. <i>Journal of Rheumatology</i> , 2019, 46, 721-726.	1.0	45
9	Safety of the Zoster Vaccine Recombinant Adjuvanted in Rheumatoid Arthritis and Other Systemic Rheumatic Disease Patients: A Single Center's Experience With 400 Patients. <i>ACR Open Rheumatology</i> , 2020, 2, 357-361.	0.9	43
10	European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 775-781.	0.5	37
11	Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1333-1339.	0.5	35
12	Complement Activation in Patients With Probable Systemic Lupus Erythematosus and Ability to Predict Progression to American College of Rheumatology-€Classified Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2020, 72, 78-88.	2.9	33
13	SLAMF7 engagement superactivates macrophages in acute and chronic inflammation. <i>Science Immunology</i> , 2022, 7, eabf2846.	5.6	31
14	Clinical and patient-reported outcomes in clinical trials of abatacept in the treatment of rheumatoid arthritis. <i>Clinical Therapeutics</i> , 2008, 30, 429-442.	1.1	30
15	Impaired Coronary Vasodilator Reserve and Adverse Prognosis in Patients With Systemic Inflammatory Disorders. <i>JACC: Cardiovascular Imaging</i> , 2021, 14, 2212-2220.	2.3	24
16	Effect of Milnacipran on Pain in Patients with Rheumatoid Arthritis with Widespread Pain: A Randomized Blinded Crossover Trial. <i>Journal of Rheumatology</i> , 2016, 43, 38-45.	1.0	20
17	Anti-PD-1 Immunotherapy-Induced Flare of a Known Underlying Relapsing Vasculitis Mimicking Recurrent Cancer. <i>Oncologist</i> , 2019, 24, 1013-1021.	1.9	15
18	Impact of certolizumab pegol on patient-reported outcomes in rheumatoid arthritis and correlation with clinical measures of disease activity. <i>Arthritis Research and Therapy</i> , 2015, 17, 343.	1.6	13

#	ARTICLE	IF	CITATIONS
19	Use of rheumatology-specific patient navigators to understand and reduce barriers to medication adherence: Analysis of qualitative findings. PLoS ONE, 2018, 13, e0200886.	1.1	11
20	Randomised prospective trial to assess the clinical utility of multianalyte assay panel with complement activation products for the diagnosis of SLE. Lupus Science and Medicine, 2019, 6, e000349.	1.1	9
21	A Multianalyte Assay Panel With Cell-Bound Complement Activation Products Predicts Transition of Probable Lupus to American College of Rheumatology-Classified Lupus. ACR Open Rheumatology, 2021, 3, 116-123.	0.9	5
22	To What Extent Can Preventive Treatments Prevent Damage From Systemic Lupus Erythematosus?. Current Rheumatology Reports, 2011, 13, 317-323.	2.1	3
23	Reductions in disease activity in the AMPLE trial: clinical response by baseline disease duration. RMD Open, 2016, 2, e000210.	1.8	3
24	Hemophagocytic Lymphohistiocytosis: The Partners Healthcare Experience over the Past 8 Years. Blood, 2014, 124, 4104-4104.	0.6	2
25	Editorial: Interferon-Targeted Therapy for Systemic Lupus Erythematosus: Are the Trials on Target?. Arthritis and Rheumatology, 2017, 69, 245-248.	2.9	1
26	Abstract 15089: Specificity for Inflammatory Pathways and Myocardial Injury Associated With Coronary Microvascular Dysfunction in Rheumatoid Arthritis. Circulation, 2020, 142, .	1.6	1
27	THU0248...UTILITY OF A MOBILE PHONE BASED APPLICATION TO COLLECT PATIENT REPORTED OUTCOME INFORMATION FROM SUBJECTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS. , 2019, , .		0
28	237...Cell bound complement activation products in combination with low complement C3 or C4 have high diagnostic yield in systemic lupus erythematosus. , 2019, , .		0
29	Marked Hyperferritinemia Does Not Predict for Hemophagocytic Lymphohistiocytosis (HLH) in the Adult Population. Blood, 2014, 124, 4951-4951.	0.6	0